Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts

Sonia Allibardi, Sergio L. Chierchia, Vittoria Margonato, Giampiero Merati, Gabriella Neri, Giacomof Dell'Antonio, Michele Samaja

Research output: Contribution to journalArticle

Abstract

The objective of this study was to test the hypothesis that the beneficial effect of trimetazidine during reflow of ischemic hearts is mediated by energy sparing and ATP pool preservation during ischemia. Isolated rat hearts (controls and rats treated with 10-6 M trimetazidine, n = 17 per group) underwent the following protocol: baseline perfusion at normal coronary flow (20 minutes), low-flow ischemia at 10% flow (60 minutes), and reflow (20 minutes). We measured contractile function, O2 uptake, lactate release, venous pH and PCO2, and the tissue content of high-energy phosphates and their metabolites. During baseline, trimetazidine induced higher venous pH and lower PCO2 without influencing performance and metabolism. During low-flow ischemia, trimetazidine reduced myocardial performance (P = 0.04) and ATP turnover (P = 0.02). During reflow, trimetazidine improved performance (91 ± 6% versus. 55 ± 6% of baseline), prevented the development of diastolic contracture and coronary resistance, and reduced myocardial depletion of adenine nucleotides and purines. ATP turnover during low-flow ischemia was inversely related to recovery of the rate-pressure product (P = 0.002), end-diastolic pressure (P = 0.007), and perfusion pressure (P = 0.05). We conclude that trimetazidine-induced protection of ischemic-reperfused hearts is also mediated by energy sparing during ischemia, which presumably preserves the ATP pool during reflow.

Original languageEnglish
Pages (from-to)543-549
Number of pages7
JournalCardiovascular Drugs and Therapy
Volume12
Issue number6
DOIs
Publication statusPublished - 1998

Fingerprint

Trimetazidine
Ischemia
Adenosine Triphosphate
Perfusion
Pressure
Purines
Adenine Nucleotides
Contracture
Lactic Acid
Phosphates
Blood Pressure

Keywords

  • ATP metabolism
  • Bioenergetics
  • Low-flow ischemia
  • Reperfusion
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Allibardi, S., Chierchia, S. L., Margonato, V., Merati, G., Neri, G., Dell'Antonio, G., & Samaja, M. (1998). Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. Cardiovascular Drugs and Therapy, 12(6), 543-549. https://doi.org/10.1023/A:1007731219206

Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. / Allibardi, Sonia; Chierchia, Sergio L.; Margonato, Vittoria; Merati, Giampiero; Neri, Gabriella; Dell'Antonio, Giacomof; Samaja, Michele.

In: Cardiovascular Drugs and Therapy, Vol. 12, No. 6, 1998, p. 543-549.

Research output: Contribution to journalArticle

Allibardi, S, Chierchia, SL, Margonato, V, Merati, G, Neri, G, Dell'Antonio, G & Samaja, M 1998, 'Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts', Cardiovascular Drugs and Therapy, vol. 12, no. 6, pp. 543-549. https://doi.org/10.1023/A:1007731219206
Allibardi, Sonia ; Chierchia, Sergio L. ; Margonato, Vittoria ; Merati, Giampiero ; Neri, Gabriella ; Dell'Antonio, Giacomof ; Samaja, Michele. / Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. In: Cardiovascular Drugs and Therapy. 1998 ; Vol. 12, No. 6. pp. 543-549.
@article{616d336c96a84a6ca4bfb47c3831de57,
title = "Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts",
abstract = "The objective of this study was to test the hypothesis that the beneficial effect of trimetazidine during reflow of ischemic hearts is mediated by energy sparing and ATP pool preservation during ischemia. Isolated rat hearts (controls and rats treated with 10-6 M trimetazidine, n = 17 per group) underwent the following protocol: baseline perfusion at normal coronary flow (20 minutes), low-flow ischemia at 10{\%} flow (60 minutes), and reflow (20 minutes). We measured contractile function, O2 uptake, lactate release, venous pH and PCO2, and the tissue content of high-energy phosphates and their metabolites. During baseline, trimetazidine induced higher venous pH and lower PCO2 without influencing performance and metabolism. During low-flow ischemia, trimetazidine reduced myocardial performance (P = 0.04) and ATP turnover (P = 0.02). During reflow, trimetazidine improved performance (91 ± 6{\%} versus. 55 ± 6{\%} of baseline), prevented the development of diastolic contracture and coronary resistance, and reduced myocardial depletion of adenine nucleotides and purines. ATP turnover during low-flow ischemia was inversely related to recovery of the rate-pressure product (P = 0.002), end-diastolic pressure (P = 0.007), and perfusion pressure (P = 0.05). We conclude that trimetazidine-induced protection of ischemic-reperfused hearts is also mediated by energy sparing during ischemia, which presumably preserves the ATP pool during reflow.",
keywords = "ATP metabolism, Bioenergetics, Low-flow ischemia, Reperfusion, Trimetazidine",
author = "Sonia Allibardi and Chierchia, {Sergio L.} and Vittoria Margonato and Giampiero Merati and Gabriella Neri and Giacomof Dell'Antonio and Michele Samaja",
year = "1998",
doi = "10.1023/A:1007731219206",
language = "English",
volume = "12",
pages = "543--549",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "6",

}

TY - JOUR

T1 - Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts

AU - Allibardi, Sonia

AU - Chierchia, Sergio L.

AU - Margonato, Vittoria

AU - Merati, Giampiero

AU - Neri, Gabriella

AU - Dell'Antonio, Giacomof

AU - Samaja, Michele

PY - 1998

Y1 - 1998

N2 - The objective of this study was to test the hypothesis that the beneficial effect of trimetazidine during reflow of ischemic hearts is mediated by energy sparing and ATP pool preservation during ischemia. Isolated rat hearts (controls and rats treated with 10-6 M trimetazidine, n = 17 per group) underwent the following protocol: baseline perfusion at normal coronary flow (20 minutes), low-flow ischemia at 10% flow (60 minutes), and reflow (20 minutes). We measured contractile function, O2 uptake, lactate release, venous pH and PCO2, and the tissue content of high-energy phosphates and their metabolites. During baseline, trimetazidine induced higher venous pH and lower PCO2 without influencing performance and metabolism. During low-flow ischemia, trimetazidine reduced myocardial performance (P = 0.04) and ATP turnover (P = 0.02). During reflow, trimetazidine improved performance (91 ± 6% versus. 55 ± 6% of baseline), prevented the development of diastolic contracture and coronary resistance, and reduced myocardial depletion of adenine nucleotides and purines. ATP turnover during low-flow ischemia was inversely related to recovery of the rate-pressure product (P = 0.002), end-diastolic pressure (P = 0.007), and perfusion pressure (P = 0.05). We conclude that trimetazidine-induced protection of ischemic-reperfused hearts is also mediated by energy sparing during ischemia, which presumably preserves the ATP pool during reflow.

AB - The objective of this study was to test the hypothesis that the beneficial effect of trimetazidine during reflow of ischemic hearts is mediated by energy sparing and ATP pool preservation during ischemia. Isolated rat hearts (controls and rats treated with 10-6 M trimetazidine, n = 17 per group) underwent the following protocol: baseline perfusion at normal coronary flow (20 minutes), low-flow ischemia at 10% flow (60 minutes), and reflow (20 minutes). We measured contractile function, O2 uptake, lactate release, venous pH and PCO2, and the tissue content of high-energy phosphates and their metabolites. During baseline, trimetazidine induced higher venous pH and lower PCO2 without influencing performance and metabolism. During low-flow ischemia, trimetazidine reduced myocardial performance (P = 0.04) and ATP turnover (P = 0.02). During reflow, trimetazidine improved performance (91 ± 6% versus. 55 ± 6% of baseline), prevented the development of diastolic contracture and coronary resistance, and reduced myocardial depletion of adenine nucleotides and purines. ATP turnover during low-flow ischemia was inversely related to recovery of the rate-pressure product (P = 0.002), end-diastolic pressure (P = 0.007), and perfusion pressure (P = 0.05). We conclude that trimetazidine-induced protection of ischemic-reperfused hearts is also mediated by energy sparing during ischemia, which presumably preserves the ATP pool during reflow.

KW - ATP metabolism

KW - Bioenergetics

KW - Low-flow ischemia

KW - Reperfusion

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=0032450739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032450739&partnerID=8YFLogxK

U2 - 10.1023/A:1007731219206

DO - 10.1023/A:1007731219206

M3 - Article

C2 - 10410824

AN - SCOPUS:0032450739

VL - 12

SP - 543

EP - 549

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 6

ER -